Does CSF1 overexpression or rearrangement influence biological behaviour in tenosynovial giant cell tumours of the knee?

Localised‐ and diffuse‐type tenosynovial giant cell tumours (TGCT) are regarded as different clinical and radiological TGCT types. However, genetically and histopathologically they seem indistinguishable. We aimed to correlate CSF1 expression and CSF1 rearrangement with the biological behaviour of different TGCT‐types with clinical outcome (recurrence).

[1]  H. Schreuder,et al.  Severity classification of Tenosynovial Giant Cell Tumours on MR imaging. , 2018, Surgical oncology.

[2]  J. Blay,et al.  Final results of ENLIVEN: A global, double-blind, randomized, placebo-controlled, phase 3 study of pexidartinib in advanced tenosynovial giant cell tumor (TGCT). , 2018 .

[3]  J. Blay,et al.  Nilotinib in locally advanced pigmented villonodular synovitis: a multicentre, open-label, single-arm, phase 2 trial. , 2018, The Lancet. Oncology.

[4]  A. Italiano,et al.  CSF-1R Inhibitor Development: Current Clinical Status , 2017, Current Oncology Reports.

[5]  H. Schreuder,et al.  Higher incidence rates than previously known in tenosynovial giant cell tumors , 2017, Acta orthopaedica.

[6]  H. Gelderblom,et al.  Limb Amputation after Multiple Treatments of Tenosynovial Giant Cell Tumour: Series of 4 Dutch Cases , 2017, Case reports in orthopedics.

[7]  A. B. Hassan,et al.  A phase I/II dose escalation and expansion study of cabiralizumab (cabira; FPA-008), an anti-CSF1R antibody, in tenosynovial giant cell tumor (TGCT, diffuse pigmented villonodular synovitis D-PVNS). , 2017 .

[8]  S. Cannon,et al.  Pigmented villonodular synovitis of the knee: A retrospective analysis of 214 cases at a UK tertiary referral centre. , 2017, The Knee.

[9]  M. Mulcahey,et al.  Pigmented Villonodular Synovitis: A Comprehensive Review and Proposed Treatment Algorithm , 2016, JBJS reviews.

[10]  J. Maher,et al.  Role of the colony-stimulating factor (CSF)/CSF-1 receptor axis in cancer. , 2016, Biochemical Society transactions.

[11]  P. Cassier,et al.  Current Systemic Treatment Options for Tenosynovial Giant Cell Tumor/Pigmented Villonodular Synovitis: Targeting the CSF1/CSF1R Axis , 2016, Current Treatment Options in Oncology.

[12]  J. Blay,et al.  CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study. , 2015, The Lancet. Oncology.

[13]  M. van de Rijn,et al.  Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor. , 2015, The New England journal of medicine.

[14]  C. Antonescu,et al.  Tenosynovial giant cell tumour/pigmented villonodular synovitis: outcome of 294 patients before the era of kinase inhibitors. , 2015, European journal of cancer.

[15]  H. Schreuder,et al.  Long-term follow-up results of primary and recurrent pigmented villonodular synovitis. , 2014, Rheumatology.

[16]  M. A. van de Sande,et al.  Functional outcome and quality of life after the surgical treatment for diffuse-type giant-cell tumour around the knee: a retrospective analysis of 30 patients. , 2014, The bone & joint journal.

[17]  B. Bjerkehagen,et al.  Novel CSF1-S100A10 fusion gene and CSF1 transcript identified by RNA sequencing in tenosynovial giant cell tumors , 2014, International journal of oncology.

[18]  J. Hung,et al.  Colony-stimulating factor 1 potentiates lung cancer bone metastasis , 2014, Laboratory Investigation.

[19]  H. Gelderblom,et al.  A multidisciplinary approach to giant cell tumors of tendon sheath and synovium—A critical appraisal of literature and treatment proposal , 2013, Journal of surgical oncology.

[20]  C. Fletcher,et al.  WHO classification of tumours of soft tissue and bone , 2013 .

[21]  L. White,et al.  Long‐term outcome of the treatment of high‐risk tenosynovial giant cell tumor/pigmented villonodular synovitis with radiotherapy and surgery , 2012, Cancer.

[22]  J. Blay,et al.  Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis , 2012, Cancer.

[23]  J. Flanagan,et al.  RNAscope: a novel in situ RNA analysis platform for formalin-fixed, paraffin-embedded tissues. , 2012, The Journal of molecular diagnostics : JMD.

[24]  R. West,et al.  Translocation and Expression of CSF1 in Pigmented Villonodular Synovitis, Tenosynovial Giant Cell Tumor, Rheumatoid Arthritis and Other Reactive Synovitides , 2007, The American journal of surgical pathology.

[25]  Robert J. Marinelli,et al.  A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[26]  H. Tanke,et al.  COBRA: combined binary ratio labeling of nucleic-acid probes for multi-color fluorescence in situ hybridization karyotyping , 2006, Nature Protocols.

[27]  B. Bjerkehagen,et al.  Molecular cytogenetic characterization of tenosynovial giant cell tumors. , 2004, Neoplasia.

[28]  M. Belosevic,et al.  Regulation of myeloid development and function by colony stimulating factors. , 2004, Developmental and comparative immunology.

[29]  P. D. Dal Cin,et al.  Molecular cytogenetic mapping of recurrent chromosomal breakpoints in tenosynovial giant cell tumors , 2002, Virchows Archiv.

[30]  H. Tanke,et al.  Simultaneous molecular karyotyping and mapping of viral DNA integration sites by 25‐color COBRA‐FISH , 2000, Genes, chromosomes & cancer.

[31]  F. Mitelman,et al.  Analysis of 35 cases of localized and diffuse tenosynovial giant cell tumor: a report from the Chromosomes and Morphology (CHAMP) study group. , 1999, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[32]  Y. Kaneko,et al.  Short arm of chromosome 1 aberration recurrently found in pigmented villonodular synovitis. , 1996, Cancer genetics and cytogenetics.

[33]  F. Mitelman,et al.  Chromosome aberrations in tenosynovial giant cell tumors and nontumorous synovial tissue , 1993, Genes, chromosomes & cancer.

[34]  J. Fletcher,et al.  Trisomy 5 and trisomy 7 are nonrandom aberrations in pigmented villonodular synovitis: Confirmation of trisomy 7 in uncultured cells , 1992, Genes, chromosomes & cancer.

[35]  M. Houman,et al.  Tissue crosslinks concentrations in normal joints and chronic articular diseases , 1997, Annals of the rheumatic diseases.